Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: James C. Williams Jr x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Objective—To test the hypothesis that feline calcium oxalate uroliths are intrinsically more resistant to comminution via shock wave lithotripsy (SWL) than canine calcium oxalate uroliths through comparison of the fragility of canine and feline uroliths in a quantitative in vitro test system.

Sample Population—Calcium oxalate uroliths (previously obtained from dogs and cats) were matched by size and mineral composition to create 7 pairs of uroliths (1 canine and 1 feline urolith/pair).

Procedure—Uroliths were treated in vitro with 100 shock waves (20 kV; 1 Hz) by use of an electrohydraulic lithotripter. Urolith fragmentation was quantitatively assessed via determination of the percentage increase in projected area (calculated from the digital image area of each urolith before and after SWL).

Results—After SWL, canine uroliths (n = 7) fragmented to produce a mean ± SD increase in image area of 238 ± 104%, whereas feline uroliths (7) underwent significantly less fragmentation (mean image area increase of 78 ± 97%). The post-SWL increase in fragment image area in 4 of 7 feline uroliths was < 50%, whereas it was > 150% in 6 of 7 canine uroliths.

Conclusions and Clinical Relevance—Results indicate that feline calcium oxalate uroliths are less susceptible to fragmentation via SWL than canine calcium oxalate uroliths. In some cats, SWL may not be efficacious for fragmentation of calcium oxalate nephroliths or ureteroliths because the high numbers of shock waves required to adequately fragment the uroliths may cause renal injury. (Am J Vet Res 2005;66:1651–1654)

Full access
in American Journal of Veterinary Research

Abstract

Objective—To determine whether a single intranasal dose of modified-live bovine respiratory syncytial virus (BRSV) vaccine protects calves from BRSV challenge and characterize cell-mediated immune response in calves following BRSV challenge.

Animals—13 conventionally reared 4- to 6-week-old Holstein calves.

Procedure—Calves received intranasal vaccination with modified live BRSV vaccine (VC-group calves; n = 4) or mock vaccine (MC-group calves; 6) 1 month before BRSV challenge; unvaccinated control-group calves (n = 3) underwent mock challenge. Serum virus neutralizing (VN) antibodies were measured on days –30, -14, 0, and 7 relative to BRSV challenge; nasal swab specimens were collected for virus isolation on days 0 to 7. At necropsy examination on day 7, tissue specimens were collected for measurement of BRSV-specific interferon gamma (IFN-γ) production. Tissue distribution of CD3+ T and BLA.36+ B cells was evaluated by use of immunohistochemistry.

Results—The MC-group calves had significantly higher rectal temperatures, respiratory rates, and clinical scores on days 5 to 7 after BRSV challenge than VCgroup calves. No difference was seen between distributions of BRSV in lung tissue of VC- and MC-group calves. Production of BRSV-specific IFN-γ was increased in tissue specimens from VC-group calves, compared with MC- and control-group calves. Virusspecific IFN-γ production was highest in the mediastinal lymph node of VC-group calves. Increased numbers of T cells were found in expanded bronchialassociated lymphoid tissue and airway epithelium of VC-group calves.

Conclusions and Clinical Relevance—An intranasal dose of modified-live BRSV vaccine can protect calves against virulent BRSV challenge 1 month later. ( Am J Vet Res 2004;65:363–372)

Full access
in American Journal of Veterinary Research

Abstract

Objective—To characterize cytokine messenger RNA (mRNA) expression in intranasally vaccinated calves after bovine respiratory syncytial virus (BRSV) challenge.

Animals—Twelve 8- to 12-week-old calves.

Procedures—Calves received modified-live BRSV vaccine (vaccinated) or spent tissue culture medium (mock-vaccinated) intranasally, followed by challenge 30 days later with BRSV, or mock challenge with spent tissue culture medium (mock-challenge controls). Interleukin-4 (IL-4) and interferon-γ (IFN-γ) mRNA was measured in lungs, bronchoalveolar lavage (BAL) fluid cells, pharyngeal tonsils, and tracheobronchial lymph nodes, and tumor necrosis factor-α (TNF-α) mRNA was measured in lungs and BAL fluid cells by reverse transcriptase-competitive polymerase chain reaction assay.

Results—Resistance to clinical signs of disease was conferred in vaccinated calves. Expression of TNF-α mRNA in lungs and BAL fluid cells was higher in mock-vaccinated calves than control or vaccinated calves. In the lung, IL-4 mRNA expression was higher in vaccinated calves than control or mock-vaccinated calves. In pharyngeal tonsils, expression of mRNA for IL-4 and IFN-γ was higher in mock-vaccinated calves than control calves. In tracheobronchial lymph nodes, IFN-γ mRNA expression was higher in mock-vaccinated calves than vaccinated calves.

Conclusions and Clinical Relevance—Although vaccinated calves had decreased clinical signs of disease after BRSV challenge, compared with mock-vaccinated calves, this difference was not related to a T helper type 1 bias, as determined by increased expression of interferon-γ mRNA relative to interleukin-4 mRNA in lungs, BAL fluid cells, or tracheobronchial lymph nodes of vaccinated calves. Pulmonary inflammation was decreased in vaccinated calves as determined by decreased expression of TNF-α mRNA. (Am J Vet Res 2004;65:725–733)

Full access
in American Journal of Veterinary Research